THE FAUCI FILES, Vol 3(4): The HIV Cocktail Hoax Unravels ... AGAIN !
January 11, 2000
Big problems for the HIV HAART Cocktail Hype Circuit -- the 12/24/99
AIDS Journal reports that delaying HAART usage does NOT affect
disease progression:
"delay (in starting the HIV cocktail drugs) does not appear to
influence the rate of clinical disease progression" ...
"The deferred initiation of therapy in these patients does not,
however, appear to translate into an increased risk of clinical
disease progression. This observation has important implications
for treatment policy and the design of future clinical trials."
Oops!
Remember all the phony "retrospective studies" of the Swiss HIV Cohort
that did their best to cherry-pick the data to find something to
feed to the HAART Hype Machine? Well, surprise, surprise - a 1/10/99
Reuters Health release stated:
"Injection drug users and individuals with low educational levels
tend to receive highly active antiretroviral therapy (HAART) later
in the course of HIV infection compared with other patients, but
this delay does not appear to influence the rate of clinical disease
progression," and "Overall, these "apparently contradictory
findings" suggest to the researchers that "...deferring
HAART may not be detrimental."
It looks like IQs have plunged for the "smart" gullibles who opted for
the "hit hard hit early" HAART Final Solution -- and, once again, the
"uneducated" were just too dumb to realize that, despite their
asymptomatic healthy condition, they "needed" those cancer drugs
to "extend their lives"... NOT !!!
Junghans et al. (1999) reveal the junk in the Fauci-sponsored
junk science known as HIV "clinical trials":
"The deferred initiation of therapy in these patients does not,
however, appear to translate into an increased risk of clinical
disease progression. This observation has important implications
for treatment policy and the design of future clinical trials."
Now perhaps the truth about the deadly "hit hard and hit early" aspect
of the HAART Hoax will begin to make sense in terms of early toxicity
and early death. Given these important findings, it becomes obvious
that the HAART HIV Cocktail Hoax was nothing less than a garish
marketing scam with the single goal of increasing drug sales.
So Toni, who do we see about all of our HAART-gullible friends who
plopped over dead while using your precious "life saving treatments"?
Why the Conspiracy of Silence, eh Toni?
Crooked Murdering Bastards!
fred
===============================
Delayed HAART does not affect clinical progression to AIDS
WESTPORT, Jan 10 (Reuters Health) - Injection drug users and individuals
with low educational levels tend to receive highly active antiretroviral
therapy (HAART) later in the course of HIV infection compared with other
patients, but this delay does not appear to influence the rate of
clinical disease progression.
These findings, reported by Dr Matthias Egger of the University of
Bristol in the United Kingdom and other members of the Swiss HIV Cohort
Study, are published in the December 24th 1999 issue of AIDS.
Dr Egger's group looked at 3342 subjects in this national prospective
multicenter study, which included 1007 women. A total of 1155 subjects
had acquired the virus through injection drug use and 1172 men became
HIV-infected through homosexual contact.
The researchers examined the use of HAART in these subjects, as well as
the effect that the timing of treatment had on clinical disease
progression. At baseline, the majority of patients (87%) did not have
AIDS. The subjects' median CD4 count was 269 cells/mL and their median
viral load was 4.3 log10 copies/mL.
After controlling for confounding factors, Dr Eggers' group found that
"...the probability of starting HAART was lower in injection drug users
compared with men who have sex with men...and in patients with minimum
schooling compared with those with vocational training."
However, the researchers found the risk of clinical disease progression
to be "...similar among men and women, patients with a history of
injection drug use, and patients with lower educational attainment in
both univariable and multivariable analysis."
Overall, these "apparently contradictory findings" suggest to the
researchers that "...deferring HAART may not be detrimental." However,
they stress that confirmation of these data with long-term clinical
trials is still needed to determine when HAART should be started.
AIDS 1999;13:2547-2554.
====================================
TITLE: Uniform risk of clinical progression despite differences in
utilization of highly active antiretroviral therapy:Swiss HIV Cohort
Study
JOURNAL: AIDS
VOLUME: 13
ISSUE: 18
PAGES: 2547-2554
RECEIVED: 8 September 1999
ACCEPTED: 23 September 1999.
AUTHOR: Cornelia Junghans*, Nicola Low*, Philip Chan*, Anne Witschiyu,
Pietro Vernazza , Matthias Egger*
ADDRESS: *MRC Health Services Research Collaboration, Department of
Social Medicine, University of Bristol, Bristol, UK; Department of
Social and Preventive Medicine, University of Berne, Berne, Switzerland;
Institute for Medical Microbiology, University of Basel, Basel,
Switzerland; Division of Internal Medicine, Cantonal Hospital St Gall,
St Gall, Switzerland
OBJECTIVE: To compare the initiation of highly active antiretroviral
therapy (HAART) in HIV-infected patients according to sex, route of HIV
acquisition and education, and to assess the impact of differences in
utilization on the probability of progression to AIDS.
DESIGN AND SETTING: Swiss HIV Cohort Study, a national prospective
multi-centre study.
PARTICIPANTS: A total of 3342 patients, including 1007 (30%) women. HIV
was acquired through injection drug use in 1155 (35%) cases and through
sex between men in 1172 (35%). Twenty-eight per cent (957) of
participants had attained only the minimum level of schooling. At
baseline, the median CD4 cell count was 269 x 106/l cells, median HIV-1
RNA was 4.3 log10 copies/ml and 2917 (87%) were free of AIDS.
METHODS: Kaplan - Meier life tables and Cox proportional hazards
regression.
RESULTS: During 7007 person-years of follow-up 2285 (69%) patients
started HAART and 318 (10%) developed a new AIDS event. In multivariable
analysis controlling for CD4 cell count, viral load and disease stage at
baseline, the probability of starting HAART was lower in injection drug
users compared with men who have sex with men, hazard ratio 0.63 (95%
confidence intervals 0.56 - 0.70) and in patients with minimum schooling
compared with those with vocational training, hazard ratio 0.82
(0.75 - 0.91). The risk of progression to AIDS was similar among men and
women, patients with a history of injecting drug use, and patients with
lower educational attainment in both univariable and multivariable
analysis.
CONCLUSION: HIV-infected injecting drug users and those with lower
levels of educational attainment start HAART later than other patient
groups. The deferred initiation of therapy in these patients does not,
however, appear to translate into an increased risk of clinical disease
progression. This observation has important implications for treatment
policy and the design of future clinical trials.
---
